Department of Veterinary Population Medicine (VPM), College of Veterinary Medicine, University of Minnesota, Saint Paul, Minnesota, USA.
Pipestone Veterinary Services, Pipestone, Minnesota, USA.
Microbiome. 2022 Aug 4;10(1):118. doi: 10.1186/s40168-022-01312-0.
Antimicrobials are used in food-producing animals for purposes of preventing, controlling, and/or treating infections. In swine, a major driver of antimicrobial use is porcine reproductive and respiratory syndrome (PRRS), which is caused by a virus that predisposes infected animals to secondary bacterial infections. Numerous antimicrobial protocols are used to treat PRRS, but we have little insight into how these treatment schemes impact antimicrobial resistance (AMR) dynamics within the fecal microbiome of commercial swine. The aim of this study was to determine whether different PRRS-relevant antimicrobial treatment protocols were associated with differences in the fecal microbiome and resistome of growing pigs. To accomplish this, we used a metagenomics approach to characterize and compare the longitudinal wean-to-market resistome and microbiome of pigs challenged with PRRS virus and then exposed to different antimicrobial treatments, and a group of control pigs not challenged with PRRS virus and having minimal antimicrobial exposure. Genomic DNA was extracted from pen-level composite fecal samples from each treatment group and subjected to metagenomic sequencing and microbiome-resistome bioinformatic and statistical analysis. Microbiome-resistome profiles were compared over time and between treatment groups.
Fecal microbiome and resistome compositions both changed significantly over time, with a dramatic and stereotypic shift between weaning and 9 days post-weaning (dpw). Antimicrobial resistance gene (ARG) richness and diversity were significantly higher at earlier time points, while microbiome richness and diversity were significantly lower. The post-weaning shift was characterized by transition from a Bacteroides-dominated enterotype to Lactobacillus- and Streptococcus-dominated enterotypes. Both the microbiome and resistome stabilized by 44 dpw, at which point the trajectory of microbiome-resistome maturation began to diverge slightly between the treatment groups, potentially due to physical clustering of the pigs. Challenge with PRRS virus seemed to correspond to the re-appearance of many very rare and low-abundance ARGs within the feces of challenged pigs. Despite very different antimicrobial exposures after challenge with PRRS virus, resistome composition remained largely similar between the treatment groups. Differences in ARG abundance between the groups were mostly driven by temporal changes in abundance that occurred prior to antimicrobial exposures, with the exception of ermG, which increased in the feces of treated pigs, and was significantly more abundant in the feces of these pigs compared to the pigs that did not receive post-PRRS antimicrobials.
The fecal microbiome-resistome of growing pigs exhibited a stereotypic trajectory driven largely by weaning and physiologic aging of the pigs. Events such as viral illness, antimicrobial exposures, and physical grouping of the pigs exerted significant yet relatively minor influence over this trajectory. Therefore, the AMR profile of market-age pigs is the culmination of the life history of the individual pigs and the populations to which they belong. Disease status alone may be a significant driver of AMR in market-age pigs, and understanding the interaction between disease processes and antimicrobial exposures on the swine microbiome-resistome is crucial to developing effective, robust, and reproducible interventions to control AMR. Video Abstract.
在食用动物中使用抗生素是为了预防、控制和/或治疗感染。在猪中,抗生素使用的主要驱动因素是猪繁殖与呼吸综合征(PRRS),这是由一种病毒引起的,使感染的动物易患继发细菌性感染。有许多抗生素方案用于治疗 PRRS,但我们对这些治疗方案如何影响商业猪粪便微生物群中的抗生素耐药性(AMR)动态知之甚少。本研究的目的是确定不同的与 PRRS 相关的抗生素治疗方案是否与生长猪的粪便微生物群和耐药组的差异有关。为了实现这一目标,我们使用宏基因组学方法来描述和比较 PRRS 病毒挑战后暴露于不同抗生素治疗的猪以及未暴露于 PRRS 病毒且抗生素暴露最小的对照组猪的纵向断奶至上市的耐药组和微生物组。从每个治疗组的猪圈级复合粪便样本中提取基因组 DNA,并进行宏基因组测序和微生物组-耐药组生物信息学和统计分析。比较了不同时间点和治疗组之间的微生物组-耐药组谱。
粪便微生物组和耐药组的组成都随时间发生了显著变化,断奶后 9 天(dpw)之间的变化非常剧烈和典型。抗生素耐药基因(ARG)的丰富度和多样性在早期更高,而微生物组的丰富度和多样性则显著降低。断奶后的转变特征是从拟杆菌主导的肠型转变为乳酸杆菌和链球菌主导的肠型。微生物组和耐药组在 44 dpw 时稳定下来,此时微生物组-耐药组成熟的轨迹开始在治疗组之间略有分歧,这可能是由于猪的物理聚集。PRRS 病毒的挑战似乎对应于许多非常罕见和低丰度的 ARG 在受挑战的猪粪便中重新出现。尽管在 PRRS 病毒挑战后接受了非常不同的抗生素暴露,但治疗组之间的耐药组组成仍然基本相似。组间 ARG 丰度的差异主要是由抗生素暴露前发生的丰度变化驱动的,除了 ermG,它在接受治疗的猪的粪便中增加,并且与未接受 PRRS 后抗生素的猪相比,在这些猪的粪便中显著更丰富。
生长猪的粪便微生物组-耐药组表现出一种由断奶和猪的生理老化驱动的典型轨迹。病毒疾病、抗生素暴露和猪的物理分组等事件对该轨迹产生了显著但相对较小的影响。因此,上市年龄猪的 AMR 谱是个体猪和所属种群的生命史的总和。疾病状况本身可能是上市年龄猪 AMR 的一个重要驱动因素,了解疾病过程与抗生素暴露对猪微生物组-耐药组的相互作用对于开发有效、稳健和可重复的干预措施来控制 AMR 至关重要。